Correlation Between CRISPR Therapeutics and Txtil Renauxview

Can any of the company-specific risk be diversified away by investing in both CRISPR Therapeutics and Txtil Renauxview at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining CRISPR Therapeutics and Txtil Renauxview into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between CRISPR Therapeutics AG and Txtil Renauxview SA, you can compare the effects of market volatilities on CRISPR Therapeutics and Txtil Renauxview and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in CRISPR Therapeutics with a short position of Txtil Renauxview. Check out your portfolio center. Please also check ongoing floating volatility patterns of CRISPR Therapeutics and Txtil Renauxview.

Diversification Opportunities for CRISPR Therapeutics and Txtil Renauxview

-0.4

Correlation Coefficient

CRISPR Therapeutics  Txtil Renauxview

Very good diversification

The 3 months correlation between CRISPR and Txtil is -0.4. Overlapping area represents the amount of risk that can be diversified away by holding CRISPR Therapeutics AG and Txtil Renauxview SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Txtil Renauxview and CRISPR Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on CRISPR Therapeutics AG are associated (or correlated) with Txtil Renauxview. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Txtil Renauxview has no effect on the direction of CRISPR Therapeutics i.e., CRISPR Therapeutics and Txtil Renauxview go up and down completely randomly.

Pair Corralation between CRISPR Therapeutics and Txtil Renauxview

Assuming the 90 days trading horizon CRISPR Therapeutics AG is expected to under-perform the Txtil Renauxview. But the stock apears to be less risky and, when comparing its historical volatility, CRISPR Therapeutics AG is 1.27 times less risky than Txtil Renauxview. The stock trades about -0.01 of its potential returns per unit of risk. The Txtil Renauxview SA is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  267.00  in Txtil Renauxview SA on October 9, 2024 and sell it today you would lose (57.00) from holding Txtil Renauxview SA or give up 21.35% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	98.39%
Values	Daily Returns

CRISPR Therapeutics AG  vs.  Txtil Renauxview SA

CRISPR Therapeutics

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in CRISPR Therapeutics AG are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, CRISPR Therapeutics is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors.

Txtil Renauxview

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Txtil Renauxview SA has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Preferred Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Pair Trading with CRISPR Therapeutics and Txtil Renauxview

The main advantage of trading using opposite CRISPR Therapeutics and Txtil Renauxview positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if CRISPR Therapeutics position performs unexpectedly, Txtil Renauxview can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Txtil Renauxview will offset losses from the drop in Txtil Renauxview's long position.

The idea behind CRISPR Therapeutics AG and Txtil Renauxview SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.